DE60133774D1 - Transkriptionsaktivierungskomplex und dessen verwendung - Google Patents

Transkriptionsaktivierungskomplex und dessen verwendung

Info

Publication number
DE60133774D1
DE60133774D1 DE60133774T DE60133774T DE60133774D1 DE 60133774 D1 DE60133774 D1 DE 60133774D1 DE 60133774 T DE60133774 T DE 60133774T DE 60133774 T DE60133774 T DE 60133774T DE 60133774 D1 DE60133774 D1 DE 60133774D1
Authority
DE
Germany
Prior art keywords
amino acid
regulatory factor
transcription regulatory
level
neurocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60133774T
Other languages
English (en)
Other versions
DE60133774T2 (de
Inventor
Norihisa Ohe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Chemical Co Ltd
Original Assignee
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co Ltd filed Critical Sumitomo Chemical Co Ltd
Application granted granted Critical
Publication of DE60133774D1 publication Critical patent/DE60133774D1/de
Publication of DE60133774T2 publication Critical patent/DE60133774T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE60133774T 2000-12-27 2001-12-17 Transkriptionsaktivierungskomplex und dessen verwendung Expired - Lifetime DE60133774T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000398548 2000-12-27
JP2000398548 2000-12-27
JP2001077740 2001-03-19
JP2001077740 2001-03-19
PCT/JP2001/011062 WO2002053735A1 (fr) 2000-12-27 2001-12-17 Complexe d'activation de transcription et son utilisation

Publications (2)

Publication Number Publication Date
DE60133774D1 true DE60133774D1 (de) 2008-06-05
DE60133774T2 DE60133774T2 (de) 2009-05-28

Family

ID=26606895

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60133774T Expired - Lifetime DE60133774T2 (de) 2000-12-27 2001-12-17 Transkriptionsaktivierungskomplex und dessen verwendung
DE60134342T Expired - Lifetime DE60134342D1 (de) 2000-12-27 2001-12-17 Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60134342T Expired - Lifetime DE60134342D1 (de) 2000-12-27 2001-12-17 Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität

Country Status (6)

Country Link
US (3) US20040110171A1 (de)
EP (3) EP1354946B1 (de)
AT (3) ATE397664T1 (de)
CA (3) CA2433501C (de)
DE (2) DE60133774T2 (de)
WO (3) WO2002053735A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190653A1 (en) * 2002-01-11 2003-10-09 Mehrdad Shamloo Regulated gene in the pathophysiology of ischemic stroke
US7618947B2 (en) 2004-08-25 2009-11-17 Isis Pharmaceuticals, Inc. Modulation of HIF-1 beta expression
JP2007282502A (ja) * 2006-03-24 2007-11-01 Sumitomo Chemical Co Ltd 細胞変性制御能力の検定方法
JP2007282501A (ja) * 2006-03-24 2007-11-01 Sumitomo Chemical Co Ltd アポトーシス制御能力の検定方法
US11889986B2 (en) 2010-12-09 2024-02-06 Endochoice, Inc. Flexible electronic circuit board for a multi-camera endoscope

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757524B1 (fr) * 1996-12-19 1999-01-29 Rhone Poulenc Rorer Sa Polypeptides de la famille bhlh, sequences d'acides nucleiques correspondantes
US5840532A (en) 1997-01-21 1998-11-24 Board Of Regents, The University Of Texas System Neuronal bHLH-PAS domain proteins
US7105647B1 (en) 1997-11-28 2006-09-12 Wisconsin Alumni Research Foundation cDNAs and proteins involved in hypoxia, circadian and orphan signal transduction pathways, and methods of use
US6780642B2 (en) * 2000-08-04 2004-08-24 Florida Atlantic University Association of SIM2 with cancer
US20030190653A1 (en) * 2002-01-11 2003-10-09 Mehrdad Shamloo Regulated gene in the pathophysiology of ischemic stroke

Also Published As

Publication number Publication date
WO2002053735A1 (fr) 2002-07-11
US20060216705A1 (en) 2006-09-28
EP1354889B1 (de) 2008-04-23
DE60133774T2 (de) 2009-05-28
CA2433495A1 (en) 2002-07-11
EP1354951A1 (de) 2003-10-22
US7129065B2 (en) 2006-10-31
US7541189B2 (en) 2009-06-02
US20040248247A1 (en) 2004-12-09
CA2433501A1 (en) 2002-07-11
EP1354889A4 (de) 2004-12-29
CA2433495C (en) 2011-10-18
ATE397664T1 (de) 2008-06-15
EP1354951B1 (de) 2008-06-04
CA2433492A1 (en) 2002-07-11
WO2002053736A1 (fr) 2002-07-11
EP1354946B1 (de) 2011-06-01
EP1354889A1 (de) 2003-10-22
EP1354946A1 (de) 2003-10-22
ATE393168T1 (de) 2008-05-15
CA2433501C (en) 2011-07-19
EP1354946A4 (de) 2005-01-05
DE60134342D1 (de) 2008-07-17
US20040110171A1 (en) 2004-06-10
WO2002053729A1 (fr) 2002-07-11
EP1354951A4 (de) 2004-12-29
ATE511539T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
ES2170220T3 (es) Procedimiento para detectar sustancias biologicamente activas.
ATE488588T1 (de) Verfahren zur kennzeichnung mesenchymaler stammzellen unter verwendung verschiedener marker
CA2403817A1 (en) Methods of modulating hair growth
GB2431013A (en) Method and apparatus for sensing a time varying current passing through an ion channel
DK0555205T3 (da) DNA, der koder for en væstfaktor, som er specifik for epitelceller
EP1170380A3 (de) Zusammensetzungen und Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening
ATE278186T1 (de) Elektrochemischer sensor zur bestimmung der blutgerinnung, ein entsprechendes blutgerinnungsmesssystem sowie ein verfahren zur bestimmung der blutgerinnung
ATE501436T1 (de) Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
ATE404867T1 (de) Verfahren und testbesteck zur beurteilung der oxidativen modifikation proteinhaltiger stoffe mittels messung ihrer antiradikalen aktivität
DE60133774D1 (de) Transkriptionsaktivierungskomplex und dessen verwendung
WO2003069341A3 (en) Method of diagnosis of inflammatory diseases using calgranulin c
DE602004017884D1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
WO2001042499A1 (fr) Procede d'essai d'agent curatif ou preventif de l'hyperlipemie
ATE520024T1 (de) Patch-clamp-verfahren und seine verwendung zur untersuchung subzellulärer merkmale
ATE365326T1 (de) Verfahren zur analyse der menge an intraabdominalem fettgewebe
WO2009125936A3 (ko) 다낭성 난소 증후군 진단을 위한 분석방법 및 키트
ATE491037T1 (de) Verfahren zum zählen von bakterien, bakterienzählgerät und für das zählgerät vewendete zelle
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
DE59710505D1 (de) Verwendung von tiefgefrorenem Blut für biologische Untersuchungsverfahren
AU2001276569B2 (en) Quantitative fluorescent assay for determining the activity of transport proteins
RU2008152780A (ru) Ген, вовлеченный в иммортализацию раковой клетки человека, и его применение
WO2003035866A1 (fr) Procede d'evaluation et d'identification de molecule biologiquement fonctionnelle a l'aide d'un gene marqueur
WO2000053735A3 (en) Methods for identifying modulators of synaptic plasticity and cell motility
DE69635355D1 (de) Verfahren zum Nachweis von biologisch aktiven Substanzen
DE60018063D1 (de) Platform für chemische und biologische analyse mit mikrowaage, analysegerät und verfahren zur verwendung derselben

Legal Events

Date Code Title Description
8364 No opposition during term of opposition